BriaCell Therapeutics Corp (BCTX) concluded trading on Thursday at a closing price of $6.03, with 40.19 million shares of worth about $242.33 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -49.51% during that period and on April 24, 2025 the price saw a gain of about 11.05%. Currently the company’s common shares owned by public are about 3.71M shares, out of which, 3.47M shares are available for trading.
Stock saw a price change of 34.60% in past 5 days and over the past one month there was a price change of 47.43%. Year-to-date (YTD), BCTX shares are showing a performance of -28.85% which decreased to -81.73% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.00 but also hit the highest price of $36.60 during that period. The average intraday trading volume for BriaCell Therapeutics Corp shares is 700.46K. The stock is currently trading 43.11% above its 20-day simple moving average (SMA20), while that difference is up 47.12% for SMA50 and it goes to -31.76% lower than SMA200.
BriaCell Therapeutics Corp (NASDAQ: BCTX) currently have 3.71M outstanding shares and institutions hold larger chunk of about 12.23% of that.
The stock has a current market capitalization of $22.37M and its 3Y-monthly beta is at 1.18. It has posted earnings per share of -$5.00 in the same period. It has Quick Ratio of 1.37 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BCTX, volatility over the week remained 28.72% while standing at 16.08% over the month.
Analysts are in expectations that BriaCell Therapeutics Corp (BCTX) stock would likely to be making an EPS of 0 in the current quarter, while forecast for next quarter EPS is 0 and it is 0 for next year. For the current quarter EPS, analysts have given the company a lowest target 0 which is 0 at the higher side of the target for the same. Stock’s fiscal year EPS is expected to drop by -16.33% while it is estimated to increase by 66.19% in next year. EPS is likely to shrink at an annualized rate of 31.60% for next 5-years, compared to annual growth of 47.85% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on February 14, 2022 offering a Buy rating for the stock and assigned a target price of $25 to it.
